Anteo Diagnostics Limited
(ASX:ADO) has emerged from a trading halt to announce revised terms for its acquisition of DIAsource ImmunoAssays in Belgium.
The original deal was for a purchase price of $24 million with a 2 year earn out to vendors. The new deal is for 50 per cent of the purchase price in cash up front and the remainder via a deferred payment plan.
The acquisition extends Anteo’s capabilities in the in vitro diagnoses sector and provides a presence in 75 countries.
Anteo reported a net loss of $4.2 million for the 2015 financial year.
